APRE (Aprea Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on APRE (Aprea Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

APRE

Aprea Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Oct 15, 2025
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Oct 14, 2025
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
Aug 28, 2025
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
Aug 12, 2025
Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer
Jun 25, 2025
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Jun 25, 2025
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
Mar 31, 2025
Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations
Mar 26, 2025
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Mar 25, 2025
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
Mar 11, 2025
Aprea Therapeutics provides update on existing patent portfolio
Feb 6, 2025
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
Feb 5, 2025
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Dec 11, 2024

Reviews